Skip to main content
Log in

Response rates, duration of response, and dose response effects in phase I studies of antineoplastics

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Over a period of 14 years, 7,960 patients were treated in 228 phase I trials. In these patients, there were 75 complete and 432 partial responses for an overall objective response rate of 6%. Complete responses lasted a median of six months (range 1–18), while partial responses lasted a median of three months (range 1–17). Of note is that no drug has made it to the market which has not had a response in phase I trials. Responses were noted in very diverse histologic types of tumors. Although there were responses at doses which were as low as 3–5% of the recommended dose for phase II trials, the majority of responses did occur at 80–120% of the dose recommended for phase II trials. Although the response rate in phase I trials is indeed low, responses do occur. This response rate information should help the clinician provide facts for the patient considering a phase I trial with new anticancer agents. These findings also emphasize that although phase I trials are characteristically dose-finding studies, if no responses are noted in phase I studies, it is unlikely the drug will be used routinely in the clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Estey F, Hoth D, Leyland-Jones B, et al.: Therapeutic results in phase I studies. Proc Am Soc Clin Oncol 3:35, 1984

    Google Scholar 

  2. Staquet MJ, Byar DP, Green SB, Rozencweig M: Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: Rationale for a three-stage strategy. Cancer Treat Rep 67:753–765, 1983

    Google Scholar 

  3. Vendetti JM: The National Cancer Institute Antitumor Drug Discovery Program, current and future perspectives: A commentary. Cancer Treat Rep 67:767–772, 1983

    Google Scholar 

  4. Salmon SE, Hamburger AW, Soehnlen B, Durie BGM, Alberts DS, Moon TE: Quantitation of differential sensitivity of human tumor stem cells to anti-cancer drugs. N Engl J Med 298:1321–1327, 1978

    Google Scholar 

  5. Alberts DS, Mackel C, Pocelinko R, Salmon SE: Phase I investigation of 9,10-anthracenedicarboxaldelydbis [4,5-dihydro-lH-imidazidfe-2-yl)hydrazone]dihydrochloride with correlative in vitro human tumor clonogenic assay. Cancer Res 42:1170–1175, 1982

    Google Scholar 

  6. Von Hoff DD, Coltman Jr CA, Forseth B: Activity of mitoxantrone in a human tumor cloning system. Cancer Res 41:1853–1855, 1981

    Google Scholar 

  7. Moertel CG, Hanley JA: The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 38:388–394, 1976

    Google Scholar 

  8. Pazdur R, Samson M, Haas C, Schilches P, Baker L: Correlation of murine antitumor models in predicting clinical drug activity in non-small cell lung cancer: A six-year experience. Proc Am Soc Clin Oncol 3:219, 1984

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Von Hoff, D.D., Turner, J. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 9, 115–122 (1991). https://doi.org/10.1007/BF00194562

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00194562

Key words

Navigation